ttp399
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
1
Phase 4
0
Earliest trial started Mar 1, 2015 (NCT02405260)
Timeline
Indications
Mechanism of action
- Hexokinase type IVACTIVATOR
GCK activator
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ttp399
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06334133 | Phase 3 | Jun 14, 2024 | vTv Therapeutics |
| NCT03335371 | Phase 1/Phase 2 (Phase 2) | Oct 25, 2017 | Juvenile Diabetes Research Foundation, vTv Therapeutics |
| NCT02405260 | Phase 2 | Mar 1, 2015 | vTv Therapeutics |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| vTv Therapeutics | For profit | 3 | 3 | 2 | 2015 |
| Juvenile Diabetes Research Foundation | Academic/Hospital | 1 | 0 | 1 | 2017 |
2 organizations
Page 1 / 1